
usd feb pm et
summari diversifi global manufactur life scienc chemic analysi instrument agil
spun-off electron measur unit
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
jan-q sale grew yoy led growth
diagnost genom group dgg
sale dgg sale driven strong
demand biopharmaceut
acg also strong quarter sale
yoy life scienc appli
growth slow yoy howev
growth prior nine month
think lsag sale slowdown relat
intensifi competit suppli life scienc
custom high-tech instrument
estim competitor thermofish
 grew life science-rel
sale respect
agil base slower growth rate
due intens competit expect revenu
growth fy oct slow
fy think adjust
ep grow much faster fy
howev driven margin improv
expens grew think
critic maintain pace product
innov lead increas price
expect diagnost genom
group sale lead growth
next sever year newli discov
applic genom field continu
rapidli expand view think
growth potenti alreadi fulli captur
agil present valuat around
materi histor forward price-to-earnings
averag also expect advers impact
tariff particularli china
key emerg market gener
agil increas adjust pre-tax
margin around fy
recent annual period driven
view strong price power innov
product effect sg cost
acquisit within high-growth area
sequenc diagnost supplement
organ growth
target fy oct
ep estim -- roughli line
histor forward price-to-earnings averag risk
view includ lower-than-expect demand
pharmaceut govern end
market unsuccess product launch
expans geograph coverag life scienc
diagnost genom research lab suppli market
think agil continu benefit posit
suppli on-going expans biopharmaceut
genom applic around world
benefit balanc intens competit howev
continu develop cut edg
technolog requir remain relev maintain
price power present technolog risk
obsolesc need ever-increas
invest view
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc provid investor exposur life scienc
diagnost appli chemic market primari product servic includ instrument
softwar servic consum entir laboratori workflow
novemb follow spin-off electron measur unit publicli trade keysight
technolog agil reorgan three busi segment life scienc appli market group
lsag fy oct sale agil crosslab group acg diagnost genom
within lsag agil focus provid application-focus solut includ instrument
softwar enabl custom identifi quantifi analyz physic biolog properti
substanc product lsag product also enabl custom life scienc research area
interrog sampl molecular cellular level lsag custom span pharmaceut valu
chain area therapeut research discoveri develop clinic trial manufactur
qualiti assur biopharmaceut market agil instrument help lower cost
discov develop new drug lsag also exposur academ govern market
includ academ institut larg govern institut privat fund organ
chemic analysi focus primarili follow area petrochem environment homeland
secur forens bioagricultur food safeti materi scienc
diagnost genom agil focus clinic academ govern
pharmaceut biotech market product fall seven main area work patholog product
specif protein flow reagent target enrich cytogenet research solut microarray
nucleic acid qualiti control molecular biolog product
agil crosslab busi span entir lab extens consum servic portfolio
design improv custom outcom major portfolio vendor neutral mean
agil serv suppli custom regardless instrument purchas choic solut rang
chemistri suppli servic softwar help connect entir lab
impact major develop may agil complet acquisit varian billion
cash per share varian lead supplier scientif instrument vacuum technolog
life scienc environment energi appli research applic june agil
complet acquisit denmark-bas dako billion largest deal histori dako
provid antibodi reagent scientif instrument softwar primarili patholog laboratori
cancer diagnost dako revenu approxim million
novemb agil spun electron measur unit separ publicli trade
compani new agil compos chemic analysi life scienc
diagnost genom unit gener billion sale presid mike mcmullen
assum ceo posit march follow retir sullivan octob agil
close nuclear magnet reson unit
financi trend total revenu grew billion fy billion fy agil adjust
pre-tax incom margin improv fy fy fy margin mark declin
fy adjust ep increas fy agil maintain conserv
leverag level ebita/interest coverag averag fy conserv debt
level allow firm focu capit alloc balanc strateg acquisit return cash
sharehold fy cash spent acquisit total million dividend share
repurchas combin million
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
budget nation institut
nih grew rapidli last three year
materi increas fund academ
govern lab turn drive sale
growth lst compani gener
materi portion revenu lab
fy nih budget grew
fy
budget increas aid lst
sub-industri sale growth
forecast
expect anoth materi nih budget
increas fy support robust
demand sub-industri product
year ahead well
addit public-fund health care
research expect larg increas privat
biopharmaceut spend drive sale
growth life scienc tool servic
sub-industri month end septemb
estim spend
increas year-over-year
spend biotech
depart research tool product
well contract research servic
 growth continu year ahead
translat continu solid sale growth
lst sub-industri
care research type prolifer
around world particularli china
emerg market turn
drive strong intern sale growth
establish life scienc tool servic
compani china particular
view howev tailwind may moder
china face slowdown econom
growth use five largest compani
lst sub-industri proxi estim
averag growth sub-industri
china-deriv sale slow
year-over-year
long-term though think china
major emerg market nation like india
need continu rapidli increas health care
expenditur parallel grow
middl class turn like continu
support strong sale growth lst
sub-industri see happen despit
potenti neg impact
import/export tariff limit
large-scal supplier option
state-of-the-art lst product outsid
compani notabl except
switzerland-bas roch
 life
rise
 life
drop
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
inc rais target
peer fy oct ep estim set
jan-q ep vs ahead view sale grew
forecast broad-bas growth see continu throughout
lsag unit rose crosslab diagnost genom
rose oper margin rose mark consecut quarter
improv margin see particular robust demand chemic unit
grew doubl digit consecut quarter /jeffrey loo cfa
analyst research note compani news
et cfra keep hold opinion share inc
keep target fy oct
ep estim -- roughli line histor forward price-to-earnings averag jan-q
ep vs ahead consensu keep fy ep
estim jan-q sale grew yoy led
growth diagnost genom group dgg sale dgg sale
driven strong demand pharma clinic end market agil
crosslab group acg also strong quarter yoy life
scienc appli market group lsag saw sale growth slow
yoy howev prior nine month think slowdown
relat intensifi competit suppli life scienc custom
high-tech instrument competitor thermofish like
gain market share agil recent quarter view base
slower growth rate due intens competit expect revenu growth
fy slow /colin scarola
et cfra keep hold opinion share agil
inc keep target
fy ep estim -- long-term averag forward price-to-earnings
expect robust demand growth co life scienc diagnost unit oct-q
ep vs ahead consensu rais fy ep
estim initi finish fiscal year
slight acceler sale growth yoy oct-q
july-q growth adj pre-tax incom oct-q yoy expect
anoth year high singl digit revenu growth fuel
strong sale china yoy oct-q grow invest
 yoy think margin improv limit
howev reduc invest plant equip
yoy last three quarter think grow faster
histor averag medium-term prospect alreadi
reflect current valuat /colin scarola
et cfra keep hold opinion share agil
keep target price in-lin
peer forward ep estim jul-q ep
vs ahead estim rais fy oct ep
estim sale foreign exchang
benefit rose -- driven solid demand china pharmaceut
chemic energi end market life scienc appli market sale rose
crosslab rose diagnost genom rose oper margin
improv basi point repres consecut quarter
year-over-year margin improv note tariff like advers
impact margin next quarter encourag steadi improv
sale oper margin see continu benefit agil diversifi
product offer geograph reach america account
sale europ asia pacif /jeffrey loo cfa
et cfra keep hold opinion share agil
lower target line peer
forward ep estim apr-q ep vs
ahead view lower fy oct estim
sale rose line forecast life scienc appli
market crosslab group diagnost genom
howev agil guid jul-q sale
mid-point year ago growth forecast agil also
guid jul-q ep initi forecast
end-market pharmaceut market remain robust sale
mass spectrometri sale chemic energi rose rise
last year howev food market mainli due impact
chines govern reorgan food safeti ministri think
reorgan slow instrument purchas china
et cfra keep hold opinion share agil
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
